Prevalence and risk factors of erectile dysfunction in COVID-19 patients: a systematic review and meta-analysis
Authors:
- 28 October 2022
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (4) , 795-804
Abstract
Purpose Studies have found that erectile dysfunction (ED) may be a short-term or long-term complication in coronavirus disease 2019 (COVID-19) patients, but no relevant studies have completed a pooled analysis of this claim. The purpose of the review was to comprehensively search the relevant literature, summarize the prevalence of ED in COVID-19 patients, assess risk factors for its development, and explore the effect of the COVID-19 infection on erectile function. Methods Medline, Embase, and the Cochrane Library was performed from database inception until April 14, 2022. Heterogeneity was analyzed by χ2 tests and I2 was used as a quantitative test of heterogeneity. Subgroup analyses, meta-regression, and sensitivity analyses were used to analyze sources of heterogeneity. Results Our review included 8 studies, 4 of which functioned as a control group. There were 250,606 COVID-19 patients (mean age: 31–47.1 years, sample size: 23–246,990). The control group consisted of 10,844,200 individuals (mean age: 32.76–42.4 years, sample size 75–10,836,663). The prevalence of ED was 33% (95% CI 18–47%, I2 = 99.48%) in COVID-19 patients. The prevalence of ED based on the international coding of diseases (ICD-10) was 9% (95% CI 2–19%), which was significantly lower than the prevalence of ED diagnosed based on the International Index of Erectile Function (IIEF-5) (46%, 95% CI 22–71%, I2 = 96.72%). The pooling prevalence of ED was 50% (95% CI 34–67%, I2 = 81.54%) for articles published in 2021, significantly higher than that for articles published in 2022 (17%, 95% CI 7–30%, I2 = 99.55%). The relative risk of developing ED was 2.64 times in COVID-19 patients higher than in non-COVID-19 patients (RR: 2.64, 95% CI 1.01–6.88). The GRADE-pro score showed that the mean incidence of ED events in COVID-19 patients was 1,333/50,606 (2.6%) compared with 52,937/844,200 (0.4%) in controls; the absolute impact of COVID-19 on ED was 656/100,000 (ranging from 4/100,000 to 2352/100,000). Anxiety (OR: 1.13, 95% CI 1.03–1.26, I2 = 0.0%) in COVID-19 patients was a risk factor for ED. Conclusion COVID-19 patients have a high risk and prevalence of ED, mainly driven by anxiety. Attention should be paid to patient’s erectile functioning when treating COVID-19.Keywords
Funding Information
- National Natural Science Foundation of China (82070560, 81470826)
- West China Hospital, Sichuan University (ZYGD18023)
This publication has 47 references indexed in Scilit:
- The Relationship Between Metabolic Syndrome, Its Components, and Erectile Dysfunction: A Systematic Review and a Meta-Analysis of Observational StudiesThe Journal of Sexual Medicine, 2015
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Anatomy, Physiology, and Pathophysiology of Erectile DysfunctionThe Journal of Sexual Medicine, 2010
- Grading quality of evidence and strength of recommendations in clinical practice guidelinesAllergy, 2009
- A Population-Based, Longitudinal Study of Erectile Dysfunction and Future Coronary Artery DiseaseMayo Clinic Proceedings, 2009
- Random-effects model for meta-analysis of clinical trials: An updateContemporary Clinical Trials, 2007
- A Bayesian fixed effects analysis of the Mantel–Haenszel model applied to meta‐analysisStatistics in Medicine, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Clinical Guidelines Panel on Erectile Dysfunction: Summary Report on the Treatment of Organic Erectile DysfunctionJournal of Urology, 1996
- Couples Therapy for Erectile Disorders: Conceptual and Clinical ConsiderationsJournal of Sex & Marital Therapy, 1991